SEC Form 4 · accession 0001209191-15-062812
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul M Silva
Officer — SVP & Corp Controller
Period of report
Jul 27, 2015
Accepted (ET)
Jul 29, 2015 · 4:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 27, 2015 | M | 1,125 | $48.74 | A | 19,500 | D | |
| Common StockF2,F3 | Jul 27, 2015 | S | 600 | $122.71 | D | 18,900 | D | |
| Common StockF3,F4 | Jul 27, 2015 | S | 400 | $123.67 | D | 18,500 | D | |
| Common Stock | Jul 27, 2015 | S | 125 | $124.80 | D | 18,375 | D | |
| Common Stock | holding | — | — | — | 169 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $48.74 | Jul 27, 2015 | M | 1,125 | D | — | Jul 24, 2022 | Common Stock | 1,125 | 4,500 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $122.71 (range $122.31 to $123.25).
- F3Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $123.67 (range $123.37 to $124.30).
- F5The option vests in 16 quarterly installments from 07/25/2012.